List of Chapters/Sections(Table Of Content)
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Radiopharmaceuticals in Nuclear Medicine Revenue
1.4 Market Analysis by Type
1.4.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Diagnostic Radiopharmaceuticals
1.4.3 Therapy Radiopharmaceuticals
1.4.4 Enriched Stable Isotopes
1.5 Market by Application
1.5.1 Global Radiopharmaceuticals in Nuclear Medicine Market Share by Application: 2022-2027
1.5.2 Diagnostic Application
1.5.3 Therapeutic Application
1.5.4 Research
1.5.5 Pharmaceutical
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Radiopharmaceuticals in Nuclear Medicine Market
1.8.1 Global Radiopharmaceuticals in Nuclear Medicine Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Radiopharmaceuticals in Nuclear Medicine Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Radiopharmaceuticals in Nuclear Medicine Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Market Share by Region (2016-2021)
3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Revenue Market Share by Region (2016-2021)
3.3 North America Radiopharmaceuticals in Nuclear Medicine Sales Volume
3.3.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.3.2 North America Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume
3.4.1 East Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.5.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.6.1 South Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.7.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.8.1 Middle East Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.9.1 Africa Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.10.1 Oceania Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.11.1 South America Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.11.2 South America Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Radiopharmaceuticals in Nuclear Medicine Sales Volume (2016-2021)
3.12.1 Rest of the World Radiopharmaceuticals in Nuclear Medicine Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Radiopharmaceuticals in Nuclear Medicine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Radiopharmaceuticals in Nuclear Medicine Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Volume Market Share by Type (2016-2021)
14.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Revenue Market Share by Type (2016-2021)
14.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Radiopharmaceuticals in Nuclear Medicine Consumption Volume by Application (2016-2021)
15.2 Global Radiopharmaceuticals in Nuclear Medicine Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Radiopharmaceuticals in Nuclear Medicine Business
16.1 Bracco Imaging S.P.A.
16.1.1 Bracco Imaging S.P.A. Company Profile
16.1.2 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Cambridge Isotope Laboratories, Inc.
16.2.1 Cambridge Isotope Laboratories, Inc. Company Profile
16.2.2 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Cardinal Health, Inc.
16.3.1 Cardinal Health, Inc. Company Profile
16.3.2 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Covidien, Plc
16.4.1 Covidien, Plc Company Profile
16.4.2 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Specification
16.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Eczacibasi-Monrol
16.5.1 Eczacibasi-Monrol Company Profile
16.5.2 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Specification
16.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Fujifilm Holdings Corporation
16.6.1 Fujifilm Holdings Corporation Company Profile
16.6.2 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Specification
16.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 GE Healthcare (Subsidiary Of General Electric Company)
16.7.1 GE Healthcare (Subsidiary Of General Electric Company) Company Profile
16.7.2 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Specification
16.7.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 IBA Group
16.8.1 IBA Group Company Profile
16.8.2 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Specification
16.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Isotec, Inc. (Sigma-Aldrich)
16.9.1 Isotec, Inc. (Sigma-Aldrich) Company Profile
16.9.2 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Specification
16.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.10 Lantheus Medical Imaging, Inc.
16.10.1 Lantheus Medical Imaging, Inc. Company Profile
16.10.2 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.11 Nordion, Inc.
16.11.1 Nordion, Inc. Company Profile
16.11.2 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.12 Ntp Radioisotopes (Pty), Ltd.
16.12.1 Ntp Radioisotopes (Pty), Ltd. Company Profile
16.12.2 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.13 Siemens Healthcare (Subsidiary Of Siemens AG)
16.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Company Profile
16.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Specification
16.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.14 Taiyo Nippon Sanso Corporation
16.14.1 Taiyo Nippon Sanso Corporation Company Profile
16.14.2 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Specification
16.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.15 Urenco Limited
16.15.1 Urenco Limited Company Profile
16.15.2 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Specification
16.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.16 Rotem Industries, Ltd., Inc.
16.16.1 Rotem Industries, Ltd., Inc. Company Profile
16.16.2 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.17 Australian Nuclear Association And Technology Organization (ANSTO)
16.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Company Profile
16.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Specification
16.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.18 Board of Radiation And Isotope Technology (BRIT)
16.18.1 Board of Radiation And Isotope Technology (BRIT) Company Profile
16.18.2 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Specification
16.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.19 Institute of Atomic Energy Polatom Radioisotope Centre
16.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Company Profile
16.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Specification
16.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.20 Institute of Isotopes Co., Ltd.
16.20.1 Institute of Isotopes Co., Ltd. Company Profile
16.20.2 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Specification
16.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.21 Institute Of Radioelement (IRE)
16.21.1 Institute Of Radioelement (IRE) Company Profile
16.21.2 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Specification
16.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Radiopharmaceuticals in Nuclear Medicine Manufacturing Cost Analysis
17.1 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Radiopharmaceuticals in Nuclear Medicine
17.4 Radiopharmaceuticals in Nuclear Medicine Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Radiopharmaceuticals in Nuclear Medicine Distributors List
18.3 Radiopharmaceuticals in Nuclear Medicine Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Radiopharmaceuticals in Nuclear Medicine (2022-2027)
20.2 Global Forecasted Revenue of Radiopharmaceuticals in Nuclear Medicine (2022-2027)
20.3 Global Forecasted Price of Radiopharmaceuticals in Nuclear Medicine (2016-2027)
20.4 Global Forecasted Production of Radiopharmaceuticals in Nuclear Medicine by Region (2022-2027)
20.4.1 North America Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.3 Europe Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.7 Africa Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.9 South America Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Radiopharmaceuticals in Nuclear Medicine Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.2 East Asia Market Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.3 Europe Market Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Countriy
21.4 South Asia Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.5 Southeast Asia Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.6 Middle East Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.7 Africa Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.8 Oceania Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.9 South America Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
21.10 Rest of the world Forecasted Consumption of Radiopharmaceuticals in Nuclear Medicine by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
